Last reviewed · How we verify
insulin pre-treatment
Insulin pre-treatment prepares the body to better utilize insulin by improving insulin sensitivity and glucose uptake before therapeutic intervention.
Insulin pre-treatment prepares the body to better utilize insulin by improving insulin sensitivity and glucose uptake before therapeutic intervention. Used for Investigational pre-treatment strategy (specific clinical indications not clearly established in public literature).
At a glance
| Generic name | insulin pre-treatment |
|---|---|
| Sponsor | University of Minnesota |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Metabolic/Endocrinology |
| Phase | FDA-approved |
Mechanism of action
This approach involves administering insulin prior to a main treatment to enhance metabolic readiness and improve the body's ability to process glucose. By pre-conditioning tissues to respond to insulin signaling, the strategy aims to optimize metabolic state and potentially improve outcomes of subsequent therapeutic interventions, particularly in contexts where glucose metabolism is relevant.
Approved indications
- Investigational pre-treatment strategy (specific clinical indications not clearly established in public literature)
Common side effects
- Hypoglycemia
- Injection site reactions
Key clinical trials
- Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance (PHASE4)
- Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity (PHASE2)
- Permissive Versus Strict Intrapartum Glucose Management in Type 1 Diabetes (PRISM-T1D) (PHASE4)
- IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion (NA)
- Effect of Ambient Temperature on Blood Glucose and Insulin Absorption in Adults With Type 1 Diabetes (NA)
- Polycystic Ovary Syndrome in Type 1 Diabetes
- Exenatide for Smoking Cessation and Prevention of Weight Gain (PHASE2)
- A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- insulin pre-treatment CI brief — competitive landscape report
- insulin pre-treatment updates RSS · CI watch RSS
- University of Minnesota portfolio CI